TABLE 3

Serial Changes in Bone Turnover Markers and BMD During Treatment with Alendronate

Marker	Baseline	Treatment with alendronate
Marker	Baseline	3 mo	6 mo	12 mo
BSALP (U/L)	27.0 (11.3)	22.6 (8.7)	19.7 (9.0)^*	18.5 (6.6)^*
NTx (nmol BCE/nmol Cr)	56.5 (22.4)	26.2 (8.4)^†	22.3 (8.0)^†	20.5 (6.2)^†
Lumbar spine SUV	5.2 (0.72)	4.8 (0.48)^*		4.4 (0.48)^†
Femoral neck SUV	2.5 (0.47)	2.2 (0.53)		1.8 (0.51)^†
Lumbar spine BMD (g/cm²)	0.78 (0.079)		0.80 (0.076)	0.84 (0.077)^*
Lumbar spine T-score	−2.2 (0.90)		−2.0 (0.73)	−1.6 (0.75)^*
Femoral neck BMD (g/cm²)	0.72 (0.093)		0.72 (0.090)	0.77 (0.084)
Femoral neck T-score	−2.9 (0.88)		−2.7 (0.85)	−2.3 (0.74)

↵* P < 0.05.
↵† P < 0.01 vs. baseline.
BCE = bone collagen equivalent; Cr = creatinine.
Data are mean followed by SD in parentheses.